At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
MRNY YieldMax MRNA Option Income Strategy ETF
Closed 07-16 16:00:00 EDT
16.72
-1.20
-6.67%
盘后16.74
+0.02+0.12%
19:54 EDT
High17.72Low16.64Vol222.11K
Open17.72D1 Closing17.92Amplitude6.03%
Mkt Cap113.78MTradable Cap113.78MTotal Shares6.80M
T/O3.82MT/O Rate3.26%Tradable Shares6.80M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Moderna President Stephen Hoge Disposes of Common Shares Worth $3.61 Million
Reuters  ·  04:46
Moderna President Stephen Hoge Disposes of Common Shares Worth $3.61 Million
Moderna Inc. Stock Sheds 7.5%, Underperforms Peers
Dow Jones  ·  04:32
Moderna Inc. Stock Sheds 7.5%, Underperforms Peers
Arbutus Biopharma, Genevant sue Pfizer, BioNTech Over Lipid Nanoparticle Patents
MT Newswires Live  ·  07-16 20:16
Arbutus Biopharma, Genevant sue Pfizer, BioNTech Over Lipid Nanoparticle Patents
Moderna Announces First Participant Dosed in Phase 1 Clinical Trial Evaluating Investigational Tumor-targeted Cancer Antigen Therapy in Solid Tumors
THOMSON REUTERS  ·  07-16 19:39
Moderna Announces First Participant Dosed in Phase 1 Clinical Trial Evaluating Investigational Tumor-targeted Cancer Antigen Therapy in Solid Tumors
Arbutus Biopharma Corp - Expects to Return up to $230 Mln in Capital to Shareholders
THOMSON REUTERS  ·  07-16 19:30
Arbutus Biopharma Corp - Expects to Return up to $230 Mln in Capital to Shareholders
Moderna Doses First Patient in Phase 1 Trial of Mrna-4200 Cancer Therapy in Solid Tumors
Reuters  ·  07-16 19:05
Moderna Doses First Patient in Phase 1 Trial of Mrna-4200 Cancer Therapy in Solid Tumors
Sanofi Sues Pfizer, Moderna over COVID Shot Technology
Reuters  ·  07-15 23:56
Sanofi Sues Pfizer, Moderna over COVID Shot Technology
Decoy Therapeutics Adds Moderna Executive Patricia Gauthier to Board
Reuters  ·  07-15 21:25
Decoy Therapeutics Adds Moderna Executive Patricia Gauthier to Board
Attovia Therapeutics, a Biopharmaceutical Firm Focused on Immune-Mediated Diseases, Files for U.S. IPO Seeking $100 Million
Stock News  ·  07-15 10:54
Attovia Therapeutics, a Biopharmaceutical Firm Focused on Immune-Mediated Diseases, Files for U.S. IPO Seeking $100 Million
Celcuity announces FDA approval of Revtorpyk
TIPRANKS  ·  07-15 04:55
Celcuity announces FDA approval of Revtorpyk
Caris Life Sciences expands prostate cancer offering with PTEN IHC testing
TIPRANKS  ·  07-14 20:35
Caris Life Sciences expands prostate cancer offering with PTEN IHC testing
BioArctic’s Partner Eisai Wins FDA Nod for At-Home Leqembi Injection in Early Alzheimer’s
TIPRANKS  ·  07-14
BioArctic’s Partner Eisai Wins FDA Nod for At-Home Leqembi Injection in Early Alzheimer’s
Jefferies Adjusts Price Target on Moderna to $60 From $53, Maintains Hold Rating
MT Newswires Live  ·  07-13
Jefferies Adjusts Price Target on Moderna to $60 From $53, Maintains Hold Rating
Moderna : Jefferies Raises Target Price to $60 from $53
THOMSON REUTERS  ·  07-13
Moderna : Jefferies Raises Target Price to $60 from $53
ETF Daily | CBRG, CBRX Jump 17%; XKRE, FBX Climb 12%; Leveraged Tech and Banks Lead
ETF Tracker  ·  07-11
ETF Daily | CBRG, CBRX Jump 17%; XKRE, FBX Climb 12%; Leveraged Tech and Banks Lead
Moderna Director Michael R. Mcdonnell Files Initial Beneficial Ownership Statement
Reuters  ·  07-11
Moderna Director Michael R. Mcdonnell Files Initial Beneficial Ownership Statement
Moderna Inc. Stock Falls 10.8%, Underperforms Peers
Dow Jones  ·  07-11
Moderna Inc. Stock Falls 10.8%, Underperforms Peers
Here’s Why Moderna Stock (MRNA) Is Crashing Today — July 10, 2026
TIPRANKS  ·  07-11
Here’s Why Moderna Stock (MRNA) Is Crashing Today — July 10, 2026
US Stocks-wall St Flat as SK Hynix's Stellar Debut Limits Losses in Chip Stocks
Reuters  ·  07-11
US Stocks-wall St Flat as SK Hynix's Stellar Debut Limits Losses in Chip Stocks
S&P 500 Top and Bottom Performing Stocks at About 12:00 P.m. EDT
Reuters  ·  07-11
S&P 500 Top and Bottom Performing Stocks at About 12:00 P.m. EDT

Introduction

Company Name.
YieldMax MRNA Option Income Strategy ETF
Affiliated Markets:
ARCA
Listing Date:
--
Main Business:
The fund advisor will seek to employ the fund's investment strategy as the fund relates to MRNA regardless of whether there are periods of adverse market, economic, or other conditions and will not seek to take temporary defensive positions during such periods. The fund is non-diversified.
Issue price:
--